Can-Fite BioPharma Ltd. CANF
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -8.57% | -16.20% | -24.72% | -57.36% | -- |
| Total Depreciation and Amortization | -93.10% | -27.78% | 242.86% | 562.50% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -63.08% | -38.41% | -16.10% | 0.46% | -- |
| Change in Net Operating Assets | -236.84% | 200.00% | 262.17% | 155.09% | -- |
| Cash from Operations | -13.86% | -15.45% | -17.18% | -48.22% | -- |
| Capital Expenditure | 0.00% | 42.86% | 60.00% | 55.56% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -366.67% | -100.00% | -100.00% | -- |
| Cash from Investing | -200,000.00% | -368.18% | -100.13% | -100.07% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -5.22% | 10.48% | 33.52% | 180.22% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 0.00% | -- |
| Cash from Financing | -0.41% | 17.22% | 43.70% | 193.97% | -- |
| Foreign Exchange rate Adjustments | -83.33% | 168.75% | 145.45% | 139.02% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -299.94% | -221.21% | 28.52% | 146.76% | -- |